Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Nature Medicine2017Vol. 23(11), pp. 1352–1361
Citations Over TimeTop 1% of 2017 papers
Xun Jin, Leo J.Y. Kim, Qiulian Wu, Lisa C. Wallace, Briana C. Prager, Tanwarat Sanvoranart, Ryan C. Gimple, Xiuxing Wang, Stephen C. Mack, Tyler E. Miller, Ping Huang, Claudia L.L. Valentim, Qi-Gang Zhou, Jill S. Barnholtz‐Sloan, Shideng Bao, Andrew E. Sloan, Jeremy N. Rich
Related Papers
- → EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer(2008)124 cited
- → Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma(2009)58 cited
- → Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients(2013)37 cited
- → EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c(2020)27 cited
- Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.(2013)